Philip S. Rudland

University of Liverpool — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

64h-index12.4kcitations322works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

S100 Proteins and Annexins(64), Cancer Cells and Metastasis(50), Protease and Inhibitor Mechanisms(28), Fibroblast Growth Factor Research(28), Cancer-related Molecular Pathways(27)

Publications322 total

FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells
International Journal of Oncology·2023· 7 citedOpen Access
Corrigendum to “Development and validation of Ran as a prognostic marker in stage I and stage II primary breast cancer” [Life Sci., 329 (2023) 121964]
Life Sciences·2023· 1 cited
Immune checkpoint inhibitor treatment of brain metastasis associated with a less invasive growth pattern, higher T-cell infiltration and raised tumor ADC on diffusion weighted MRI
Cancer Immunology Immunotherapy·2023· 5 citedOpen Access
Development and validation of Ran as a prognostic marker in stage I and stage II primary breast cancer
Life Sciences·2023· 8 cited
Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells
Biomolecules·2023· 15 citedOpen Access
Supplementary Figure 10 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 8 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 4 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 1 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary materials and methods from S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer
2023Open Access
Supplementary Tables 1-3 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 9 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure Legends 1-10 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 5 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Suplementary Figures from S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer
2023Open Access
Supplementary Figure 8 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Methods and Materials from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 10 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary methods from T-Cell Densities in Brain Metastases Are Associated with Patient Survival Times and Diffusion Tensor MRI Changes
2023Open Access
Data from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
page 1 of 17Next →

Frequent Co-authors

Roger Barraclough(19), Angela Platt‐Higgins(11), John Winstanley(7), Suzete de Silva Rudland(6), W. Seifert(5), Youqiang Ke(5), Mohamed El‐Tanani(4), Michael P.A. Davies(4), D. Ross Sibson(4), David G. Fernig(4), Christine Renshaw(3), Christopher R. West(3), E. Jane Ormerod(3), Dong L. Barraclough(3), Luis Jiménez de Asúa(3), F C Campbell(3), Carol Beesley(3), Hiroshi Fujii(3), Paul H. Smith(3), Sam Leinster(3)